Journal of blood medicine · 2026
Evaluation of Determinants of Intraoperative Blood Loss During Craniotomy for Brain Tumors: A Retrospective Single-Center Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zahara Riza, Pramodana Bintang, Firdaus Riyadh, Monika Tesha Islami, Renoza Radea
Аннотация
BACKGROUND: Inefficient blood product management in craniotomy for tumor removal poses clinical and economic burdens. This study evaluates predictive factors for significant intraoperative blood loss to establish a robust perioperative risk stratification model.
MATERIALS AND METHODS: This retrospective cohort study examined adults undergoing elective brain tumor resections between 2020 and 2024 at a national tertiary referral center. Our primary outcome was significant blood loss, defined as an estimated loss of at least 20% of the patient's total blood volume (EBV). Independent predictors were evaluated using multivariate logistic regression, specifically backward-elimination methods.
RESULTS: Out of 378 patients, 35% of patients experienced significant intraoperative blood loss. Bivariate analysis showed female gender, meningioma pathology, cerebral sinus involvement, tumor size ≥ 5 cm, and operation time ≥ 300 minutes associated with higher blood loss (p < 0.05). In the final multivariate model, tumor size ≥ 5 cm was the primary independent predictor (adjusted Odds Ratio [aOR] = 2.736; 95% Confidence Interval [CI]: 1.746-4.285; p < 0.001), followed by meningioma pathology (aOR = 2.104; 95% CI: 1.292-3.426; p = 0.003). Operation time ≥ 300 minutes in the final model (aOR = 1.703) was retained due to its clinical relevance in the operating room.
CONCLUSION: Tumor size ≥ 5 cm and meningioma pathology were independently associated with significant intraoperative blood loss. Utilizing these factors as a preoperative screening tool allows clinical teams to anticipate significant blood loss, optimize cross-matching, and reduce institutional resource wastage.
MATERIALS AND METHODS: This retrospective cohort study examined adults undergoing elective brain tumor resections between 2020 and 2024 at a national tertiary referral center. Our primary outcome was significant blood loss, defined as an estimated loss of at least 20% of the patient's total blood volume (EBV). Independent predictors were evaluated using multivariate logistic regression, specifically backward-elimination methods.
RESULTS: Out of 378 patients, 35% of patients experienced significant intraoperative blood loss. Bivariate analysis showed female gender, meningioma pathology, cerebral sinus involvement, tumor size ≥ 5 cm, and operation time ≥ 300 minutes associated with higher blood loss (p < 0.05). In the final multivariate model, tumor size ≥ 5 cm was the primary independent predictor (adjusted Odds Ratio [aOR] = 2.736; 95% Confidence Interval [CI]: 1.746-4.285; p < 0.001), followed by meningioma pathology (aOR = 2.104; 95% CI: 1.292-3.426; p = 0.003). Operation time ≥ 300 minutes in the final model (aOR = 1.703) was retained due to its clinical relevance in the operating room.
CONCLUSION: Tumor size ≥ 5 cm and meningioma pathology were independently associated with significant intraoperative blood loss. Utilizing these factors as a preoperative screening tool allows clinical teams to anticipate significant blood loss, optimize cross-matching, and reduce institutional resource wastage.